Q-omics provides the consensus-scored ZFYVE21 profile across patient tissues and cancer cell-line models. ZFYVE21 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, ZFYVE21 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, ZFYVE21 protein abundance shows 24,319 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ESCA, THCA, and LUAD as cancer lineages where ZFYVE21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFYVE21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFYVE21 survival associations across molecular data types. ZFYVE21 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFYVE21 RNA expression–survival associations across cancer types. High ZFYVE21 expression shows unfavorable associations in DLBC, STAD, CESC and ACC, but favorable associations in ESCA and KIRC. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for ZFYVE21 RNA expression.
This table summarizes ZFYVE21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZFYVE21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFYVE21 shows lower tumor expression in THCA, KIRC, LUAD, UCEC and BRCA and higher tumor expression in CHOL. The THCA box plot shows higher ZFYVE21 RNA expression in normal versus tumor tissue (log2 FC = −0.887, t-test p < 0.001).
This table shows molecular features associated with ZFYVE21 in patient tissues and cancer cell lines. In patient samples, ZFYVE21 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFYVE21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
